Skip to main content

Table 3 Pharmacokinetics of scFv(FRP5)-ETA

From: Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas

Dose level (μg/kg)

Peak concentration range (ng/ml)

Peak concentration mean (ng/ml)

AUC (ng* hour/ml)

Plasma clearance (l/hour)

Half-life (hours)

2

n.d.

n.d.

n.d.

n.d.

n.d.

4

18–49

39 ± 18

39 ± 1

6.6 ± 0.6

0.55 ± 0.02

10

128–129

129 ± 1

138 ± 64

5.3 ± 2.1

0.74 ± 0.27

12.5

93–204

160 ± 35

178 ± 100

4.9 ± 3.1

0.73 ± 0.30

20

115–307

236 ± 105

326 ± 146

3.8 ± 2.2

0.73 ± 0.22

  1. AUC, area under the concentration–time curve; n.d., not determined.